综述:乙型肝炎——当前与新兴疗法
本文综述慢性乙型肝炎现有与新兴治疗。现有聚乙二醇干扰素α-2a和核苷(酸)类似物均不能实现完全治愈,罕见实现功能性治愈。针对病毒生命周期多环节及免疫调节的新疗法正在临床试验中,有望实现功能性治愈。
要点
- 现有治疗不能实现完全治愈,罕见实现功能性治愈(HBsAg清除)。
- 新兴疗法靶点包括病毒进入、cccDNA、转录、核心蛋白、HBsAg释放和聚合酶。
- 免疫调节策略包括靶向固有和适应性免疫及治疗性疫苗。
核心结论
- 在研新疗法的广度和范围为实现功能性治愈的方案带来希望。
研究设计与样本
- 综述:检索PubMed、clinicaltrials.gov、主要会议摘要和制药网站,汇总当前与新兴乙型肝炎疗法。
主要发现
- 现有治疗不能实现完全治愈(cccDNA和整合HBV DNA清除),罕见实现功能性治愈(HBsAg清除)。
- 新兴疗法靶向病毒进入、cccDNA、病毒转录、核心蛋白、HBsAg释放和HBV聚合酶。
- 免疫调节方法包括靶向固有免疫和适应性免疫以及治疗性疫苗接种。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The hepatitis B virus (HBV) affects an estimated 290 million individuals worldwide and is responsible for approximately 900 000 deaths annually, mostly from complications of cirrhosis and hepatocellular carcinoma. Although current treatment is effective at preventing complications of chronic hepatitis B, it is not curative, and often must be administered long term. There is a need for safe, effective, finite duration curative therapy. AIM: Our aim was to provide a concise, up to date review of all currently available and emerging treatment options for chronic hepatitis B. METHODS: We conducted a search of PubMed, clinicaltrials.gov, major meeting abstracts and pharmaceutical websites for publications and communications on current and emerging therapies for HBV. RESULTS: Currently approved treatment options for chronic hepatitis B include peginterferon alpha-2a and nucleos(t)ide analogues. Both options do not offer a 'complete cure' (clearance of covalently closed circular DNA (cccDNA) and integrated HBV DNA) and rarely achieve a 'functional cure' (hepatitis B surface antigen (HBsAg) loss). An improved understanding of the viral lifecycle, immunopathogenesis and recent advances in drug delivery technologies have led to many novel therapeutic approaches that are currently being evaluated in clinical trials including targeting of viral entry, cccDNA, viral transcription, core protein, and release of HBsAg and HBV polymerase. Additionally, novel immunological approaches that include targeting the innate and adaptive immune system and therapeutic vaccination are being pursued. CONCLUSION: The breadth and scope of novel therapies in development hold promise for regimen/s that will achieve functional cure.
引用
- Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther. 2022. PMID: 35224760. doi:10.1111/apt.16828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。